What is Apogee Therapeutics, Inc. Common Stock (APGE) stock price today?

Apogee Therapeutics, Inc. Common Stock (APGE) currently trades at $82.03 per share. The stock has a market capitalization of $6.39B and a P/E ratio of —x.

Is APGE stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Apogee Therapeutics, Inc. Common Stock has a Smart Value Score of 25/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 2/9 and Altman Z-Score is 10.55.

Is Apogee Therapeutics, Inc. Common Stock financially healthy?

Apogee Therapeutics, Inc. Common Stock's Piotroski F-Score is 2/9 (weak financial health). The Altman Z-Score of 10.55 places it in the safe zone.

APGE

Apogee Therapeutics, Inc. Common Stock

NASDAQ: APGE · HEALTHCARE · BIOTECHNOLOGY

$82.03

-3.91% today

Updated 2026-04-29

Market cap

$6.39B

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-4.22

Dividend yield

—

52W range

$34 – $95

Volume

0.9M

Market cap

$6.39B

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-4.22

Dividend yield

—

52W range

$34 – $95

Volume

0.9M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

7.3

Quality

B+

3.0

Profitability

5.0

Valuation

C+

2/9

Piotroski F-Score

Weak

10.6

Altman Z-Score

Safe zone

—

Industry rank

—

View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target

$116.87

+42.47%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

0 Strong Buy14 Buy3 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Altman Z 10.55 — safe zone

Risks

- Piotroski 2/9 — weak financial health

- Thin margins at 0.00%

- Negative free cash flow $-62.75M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Net income	$-39.78M	$-83.98M	$-182.15M	$-255.84M	$-69.39M
EPS	—	—	—	—	$-4.22
Free cash flow	$-16.43M	$-74.93M	$-172.33M	$-232.60M	$-62.75M
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
APGE	$6.39B	25	4.3	3.0	5.0	7.3	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$336.47B	54	5.3	5.5	7.3	4.8	+42.09%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Apogee Therapeutics, Inc. Common Stock trades at $82.03. Our Smart Value Score of 25/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of 10.55, it sits in the safe zone.

Frequently asked questions

What is Apogee Therapeutics, Inc. Common Stock's stock price?

Apogee Therapeutics, Inc. Common Stock (APGE) trades at $82.03.

Is Apogee Therapeutics, Inc. Common Stock overvalued?

Smart Value Score 25/100 (Grade F, Strong Sell).

What is the price target of Apogee Therapeutics, Inc. Common Stock (APGE)?

The analyst target price is $116.87, representing +42.5% upside from the current price of $82.03.

Piotroski F-Score?

2/9 — weak financial health.

Altman Z-Score?

10.55 — safe zone.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio—

ROE-31.60%

Beta1.03

50D MA$77.38

200D MA$60.71

Shares out0.06B

Float0.05B

Short ratio—

Avg volume0.9M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

APGE vs LLY →APGE vs JNJ →APGE vs ABBV →Stock screener →